1 |
Barbara M, Bolten MS, Matthew Drapeau MBA, et al (2010). Strategic Overview of the Targeted Cancer Therapies Marketplace. http://decisionresources.com/.
|
2 |
Baselga J, Perez EA, Pienkowski T, Bell R (2006). Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist, 11, 4-12.
DOI
|
3 |
Blumenthal D (2004). Doctors and drug companies. N Engl J Med, 351, 1885-90.
DOI
|
4 |
Cohen EE (2008). mTOR: the mammalian target of replication. J Clin Oncol, 26, 348-9.
DOI
|
5 |
Coiffier B, Thieblemont C, Van Den Neste E, et al (2010). Longterm outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116, 2040-5.
DOI
|
6 |
DiMasi JA, Hansen RW, Grabowski HG (2003). The price of innovation: new estimates of drug development costs. J Health Econ, 22, 151-85.
DOI
|
7 |
Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391-400.
DOI
ScienceOn
|
8 |
Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6.
DOI
|
9 |
Grillo-Lopez AJ, White CA, Varns C, et al (1999). Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol, 26, 66-73.
|
10 |
Hallberg B, Palmer RH (2010). Crizotinib-latest champion in the cancer wars? N Engl J Med, 363, 1760-2.
DOI
ScienceOn
|
11 |
Hornberger JC, Best JH (2005). Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer, 103, 1644-51.
DOI
|
12 |
Http://ramoslink.info/pubs/GlivecPAP.pdf : (2010). NICE denies availability of Sorafenib liver cancer drug on NHS, http://www.news-medical.net.
|
13 |
Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90.
DOI
ScienceOn
|
14 |
Maggon K (2007). Monoclonal antibody "gold rush". Curr Med Chem, 14, 1978-87.
DOI
|
15 |
Mok TS, Wu YL, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
DOI
|
16 |
Murawski N, Pfreundschuh M (2010). New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol, 11, 1074-85.
DOI
|
17 |
Ocana A, Amir E, Seruga B, Pandiella A, et al (2010). Do we have to change the way targeted drugs are developed? J Clin Oncol, 28, 420-1.
DOI
|
18 |
Ronald D, Levy DGM, Miller R (2008). Targeted Therapy for B-Cell Lymphoma: The Story of Rituximab. Special ASH 50th anniversary brochure.
|
19 |
Rosenwald A, Wright G, Chan WC, et al (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346, 1937-47.
DOI
ScienceOn
|
20 |
Spurling GK, Mansfield PR, Montgomery BD, et al (2010). Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med, 7, 1000352.
|
21 |
Staff Writer (2010). FDA considers revoking approval of Avastin for advanced breast cancer. Washington Post. Washington.
|
22 |
Valentino L, Pierre J (2006). JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol, 71, 713-21.
DOI
|
23 |
van Oosterom AT, Judson I, Verweij J, et al (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 358, 1421-3.
DOI
ScienceOn
|